Exhibit 99.1
Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Bausch + Lomb
08/06/2013
LAVAL, Quebec, Aug. 6, 2013 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has completed the previously announced acquisition of Bausch + Lomb Holdings Incorporated. Bausch + Lomb is a leading global eye health company that has a broad portfolio of eye health products, including well-known prescription and OTC brandsBesivance, Lotemax, OcuviteandPreserVision;vision care brandsBiotrue ONEday,PureVision, renuandBoston;andsurgical brands enVista, Storz, Stellarisand VICTUS.
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found atwww.valeant.com.
(Logo:http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)
Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com
SOURCE Valeant Pharmaceuticals International, Inc.